Leadless pacemaker implant, anticoagulation status, and outcomes: Results from the Micra Transcatheter Pacing System Post-Approval Registry

医学 心房颤动 植入 永久起搏器 外科 内科学 心脏病学
作者
Mikhael F. El‐Chami,Christophe Garweg,Saverio Iacopino,Faisal Al-Samadi,José Luis Martínez‐Sande,Claudio Tondo,Jens Brock Johansen,Xavier Viñolas Prat,Jonathan P. Piccini,Yong‐Mei Cha,Eric Grubman,Pierre Bordachar,Paul R. Roberts,Kyoko Soejima,Kurt Stromberg,Dedra H. Fagan,Nicolas Clémenty
出处
期刊:Heart Rhythm [Elsevier BV]
卷期号:19 (2): 228-234 被引量:11
标识
DOI:10.1016/j.hrthm.2021.10.023
摘要

Early results from the Micra investigational trial and Micra Post-Approval Registry (PAR) demonstrated excellent safety and device performance; however, outcomes based on anticoagulation (AC) status at implant have not been evaluated.The purpose of this study was to report implant characteristics, perforation rate, and vascular-related events based on perioperative oral AC strategy in patients undergoing Micra implant.We compared procedure characteristics, major complications, and vascular events, including pericardial effusion, stratified by any adverse event (including major complications, minor complications, and observations) or major complication only according to AC status in the Micra PAR.Among 1795 patients with AC status available, 585 were not on AC, 795 had AC interrupted, and 415 had AC continued during Micra implant. Non-AC patients tended to be younger, with less history of atrial fibrillation and chronic obstructive pulmonary disease, and more history of dialysis than interrupted and continued patients. The implant success rate was similar for all groups (99.1%-99.8%). Through 30 days postimplant, the overall major complication rate was 3.1% for the non-AC group, 2.6% for the interrupted group, and 1.5% for the continued group. The combined rate for any vascular or pericardial effusion adverse event did not differ significantly among AC strategies (6.5%, 4.8%, and 3.6%, respectively).Implant of Micra seems to be safe and feasible regardless of an interrupted or continued periprocedural oral AC strategy, with no increased risk of perforation or vascular complications.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
哈哈哈发布了新的文献求助10
刚刚
六六发布了新的文献求助10
刚刚
cfy完成签到,获得积分20
1秒前
鲤鱼平蓝完成签到,获得积分10
1秒前
cici完成签到 ,获得积分10
2秒前
3秒前
wang完成签到,获得积分10
3秒前
Nole的应助被忧郁的若菱采纳,获得10
4秒前
方好完成签到 ,获得积分10
4秒前
CipherSage的应助被suchui采纳,获得10
4秒前
fuze发布了新的文献求助10
5秒前
鲤鱼平蓝发布了新的文献求助10
6秒前
Naruto完成签到,获得积分10
7秒前
Qml完成签到,获得积分10
8秒前
8秒前
言儿发布了新的文献求助10
8秒前
怡然的扬完成签到,获得积分10
8秒前
蜡笔完成签到,获得积分10
8秒前
丘比特的应助被陈老派采纳,获得10
9秒前
科研通AI6.2的应助被Ruuko采纳,获得10
9秒前
无花果的应助被ggdh采纳,获得10
9秒前
10秒前
讨喜完成签到,获得积分10
11秒前
11秒前
JACS发布了新的文献求助10
11秒前
liudonghai完成签到,获得积分10
12秒前
大模型的应助被Naruto采纳,获得10
12秒前
Estrella的应助被蜡笔采纳,获得10
12秒前
hepote发布了新的文献求助10
12秒前
李健的小迷弟的应助被啦啦啦采纳,获得10
13秒前
13秒前
13秒前
nihao发布了新的文献求助10
14秒前
14秒前
研友_Lpawrn完成签到,获得积分10
14秒前
bkagyin的应助被huidann采纳,获得50
14秒前
DW的应助被w1x2123采纳,获得10
14秒前
16秒前
Jennifer的应助被Juliette采纳,获得20
17秒前
suchui发布了新的文献求助10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8168163
求助须知:如何正确求助?哪些是违规求助? 9561243
关于积分的说明 21759855
捐赠科研通 7759477
什么是DOI,文献DOI怎么找? 3429959
关于科研通互助平台的介绍 2553757
邀请新用户注册赠送积分活动 2474496